← Back to Search

Atrial Fibrillation Screening for Cancer Patients (SARIC Trial)

N/A

Recruiting

Led By Zain Asad, MD

Research Sponsored by University of Oklahoma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male and female patients age ≥65 with a current diagnosis or history of cancer.

The age is restricted to ≥65 years because prevalence of AF is extremely low. .

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will study if screening for AF in cancer patients can detect the condition earlier and improve treatment outcomes.

Who is the study for?

This trial is for men and women aged 65 or older who have been diagnosed with cancer, including those currently undergoing or with a history of chemotherapy, radiotherapy, or cancer-related surgeries. It's focused on detecting atrial fibrillation (AF), which is more common in the cancer population.

What is being tested?

The study tests if a quick, 30-second ECG using Kardia Mobile can spot AF better than routine care in older adults with cancer. This randomized controlled trial aims to find out whether early detection leads to improved treatment outcomes.

What are the potential side effects?

Since this trial involves non-invasive screening with an ECG device and standard medical care, side effects are minimal. However, there may be indirect consequences from any subsequent treatments initiated as a result of the screening findings.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 65 or older with a current or past cancer diagnosis.

Select...

I am 65 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The Investigators will compare the incidence of newly diagnosed AF identified by screening versus usual care

Secondary study objectives

To determine the effect of screening-detected AF on initiation of anticoagulation.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Screen groupActive Control1 Intervention

Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.

Group II: Usual CareActive Control1 Intervention

For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.

0 / 2Eligibility criteria met